描述

DNA repair drugs are used in repairing damaged DNA and for treating cancers. DNA damage can affect normal cell replicative function and impact rates of apoptosis. Alternatively, damage to genetic material can result in impaired cellular function, cell loss, or the transformation of healthy cells to cancers. The global DNA repair drugs market is poised to grow by US$ 45.5 亿期间 2022-2028, 复合年增长率为 19.8% 在预测期内, 据数据和分析公司 StrategyHelix 称.

该报告提供了该时期的最新市场规模数据 2018-2021 并预测到 2028 covering key market aspects like sales value for DNA repair drugs. The global DNA repair drugs market is segmented on the basis of application, 和地区. 按申请, the global DNA repair drugs market has been segmented into breast cancer, ovarian cancer. The breast cancer segment was the largest contributor to the global DNA repair drugs market in 2021. 地理上, the global DNA repair drugs market is segmented into Asia Pacific, 欧洲, 北美, 世界其他地区 (排). 据研究, North America had the largest share in the global DNA repair drugs market.

The global DNA repair drugs market is highly competitive. Key companies profiled in the report include Abbott Laboratories, 艾伯维公司, Amgen Inc., AstraZeneca plc, 拜耳公司, 礼来公司, Gilead Sciences Inc., 葛兰素史克公司 (葛兰素史克), 约翰逊 & 约翰逊, Merck KGaA, Novartis AG, Pfizer Inc., Roche Holding AG, 赛诺菲公司, The Bristol-Myers Squibb Company (BMS).

该报告对于活跃在该行业的公司和组织来说是宝贵的资源. It provides a cohesive picture of the DNA repair drugs market to help drive informed decision making for industry executives, 政策制定者, 学术的, 和分析师.

报告范围

应用: breast cancer, ovarian cancer
地区: 亚太地区, 欧洲, 北美, 世界其他地区 (排)
考虑的年数: 本报告涵盖期间 2018 到 2028

利益相关者的主要好处

– Get a comprehensive picture of the global DNA repair drugs market
– 精准定位增长领域和投资趋势

目录

部分 1. 介绍
– 研究范围
– 学习时段
– 地理范围
– 研究方法论
部分 2. DNA repair drugs market overview
部分 3. 按应用划分的市场细分
– 乳腺癌
– Ovarian cancer
部分 4. 按地区划分的市场细分
– 亚太地区
– 欧洲
– 北美
– 世界其他地区 (排)
部分 5. 重点企业
– 雅培实验室
– 艾伯维公司.
– Amgen Inc.
– AstraZeneca plc
– 拜耳公司
– 礼来公司
– Gilead Sciences, 公司.
– 葛兰素史克公司 (葛兰素史克)
– 约翰逊 & 约翰逊
– Merck KGaA
– Novartis AG
– Pfizer Inc.
– Roche Holding AG
– 赛诺菲公司.
– The Bristol-Myers Squibb Company (BMS)
关于StrategyHelix
免责声明